Supporting Information

Divergent Synthesis of Hydropyridine Derivatives via Nitrogen-Containing Lewis Base Mediated Regioselective [4+2] Cyclizations

Hongxing Jin, Erqing Li, You Huang*

- 1. State Key Laboratory and Institute of Elemento-Organic Chemistry, College of Chemistry, Nankai University, Tianjin 30071, China
- 2. Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 30071, China

E-mail: hyou@nankai.edu.cn

Table of Contents

I. General information	S2
II. Preparation of the allenic esters	S2
III. Preparation of the α , β -unsaturated cyclic ketimines	S2
IV. References	S3
V. General procedure and spectroscopic data and HPLC chromatogram	S3
VI. X-Ray crystal structure of 3k and 4k	S59

I. General information

All the starting materials were obtained from commercial sources and used without further purification unless otherwise stated. Yields referred to isolated compounds through flash column chromatography performed using 300-400 mesh silica gel. NMR spectra were recorded on Varian Brucker ARX 400 spectrometer in CDCl₃ solution and the chemical shifts were reported in parts per million (ppm) relative to internal standard TMS (0 ppm) for ¹H NMR and chloroform-*d* (77.0 ppm) for ¹³C NMR. Coupling constants were given in Hertz (Hz). Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublet), brs (broad singlet) and m (multiplet). Infrared spectra (IR) spectra were recorded on a Perkin-Elmer 983G instrument. High resolution mass spectrometry (HRMS) were obtained on an IonSpec FT-ICR mass spectrometer with ESI or MALDI resource. Melting points were measured on a RY-I apparatus and are reported uncorrected.

II. Preparation of the allenic esters



Allenic esters is a known compound and synthesized according to a similar method developed by Hansen ^[1]. To a solution of benzyl (triphenylphosphoranylidene)acetate (0.1 mol) in CH₂Cl₂ (500 mL) was added 1.1 equivalent of Et₃N (0.11 mol). After stirred for about 15 minutes, 1.1 equivalent of acetyl chloride (0.11 mol) was added dropwise. Then the reaction mixture was stirred overnight at room temperature and was carefully evaporated to remove most of the solvent, and then the residue was extracted by petroleum ether (b.p. 30-60 °C, 5×200 mL). The combined extracting was concentrated and the residue was subjected to column chromatography (eluant: 5 % EtOAc in petroleum ether) to provide the allenic esters as light yellow oil.

III. Preparation of the α , β -unsaturated cyclic ketimines



The Synthesis of B: To a flame dried 500 mL round bottle flask with a magnetic

stirring bar under Argon atmosphere was added saccharin **A** (0.030 mol, 5.49 g) and anhydrous THF (250 mL). The flask was cooled to -78 °C and 2 equiv (0.060 mol) of the appropriate lithium reagent were carefully added by syringe or cannula. The reaction was stirred at -78 °C for an additional 4 h, then 100 mL of H₂O was added, and the reaction mixture was warmed to room temperature. The solution was transferred to a separatory funnel where 200 mL of ether was added and the aqueous layer was separated. The organic layer was washed successively with 10% HCl (2×100 mL), 10% NaHCO₃ (2×125 mL), and 100 mL of H₂O and dried over anhydrous MgSO₄. Removal of the solvent in vacuo gave a white solid, which was crystallized from absolute ethanol to give sulfonimine ^[2].

The Synthesis of 1: Piperidine (1 mmol) and acetic acid (1 mmol) were added to a solution of **B** (3-methyl-1,2-benzoisothiazole-1,1-dioxide) (10 mmol) and aldehyde (10 mmol) in EtOH and the mixture was refluxed for 3 hours. The mixture was cooled to 0 °C and the solid was collected by filtration, washed with cold EtOH, and dried to afford products **1** in 49-86% yield. They were generally used without further purification ^[3].

IV. References

- [1] Lang, R. W.; Hansen, H.-J. Organic Syntheses. 1990, 62, 202-206.
- [2] Davis, F. A.; Towson, J. C.; Vashi, D. B.; ThimmaReddy, R.; McCauley, J. P.; Jr.;
 Harakal, M. E.; Gosciniak, D. J. J. Org. Chem., 1990, 55, 1254-1261.
- [3] (a) Feng, X.; Zhou, Z.; Ma, C.; Yin, X.; Li, R.; Dong, L.; Chen, Y.-C. Angew. Chem. Int. Ed. 2013, 52, 14173-14176. (b) Li, E.; Jin, H.; Jia, P.; Dong, X.; Huang, Y. Angew. Chem. Int. Ed. 2016, 55, 11591-11594.

V. General procedure and spectroscopic data and HPLC chromatogram

Formal Synthesis processes for racemic systems:

To a stirred solution of 1 (0.1 mmol) and 2 (0.12 mmol) in CH_2Cl_2 or CH_3CN (2.0 mL or 1 mL) at 40 °C or 60 °C, catalyst DMAP/DABCO was added in one portion. Then the reaction mixture was stirred at this temperature. After completion of the reaction (monitored by TLC), the reaction mixture was purified by flash chromatography on silica gel (EtOAc/petroleum ether) to give cycloadduct **3** and **4**.

Formal Synthesis processes for racemic systems:

To a stirred solution of 1c (0.1 mmol) and 2a (0.12 mmol) in solvent (1 mL) at 25 °C, the chiral catalyst was added in one portion. Then the reaction mixture was stirred at this temperature. And the reaction was monitored by TLC, the reaction mixture was purified by flash chromatography on silica gel (EtOAc/petroleum ether) to give cycloadduct 3c and 4c (for details see below).



6	Cat. 2	CH ₃ CN	120 h	no product		
7	Cat. 2	Toluene	120 h	no product		
8	Cat. 2	THF	120 h	trace, no detected	no product	
9	Cat. 3	CH_2Cl_2	120 h	complex sys	tem, no detected	
10	Cat. 3	CH ₃ CN	120 h	no	product	
11	Cat. 3	Toluene	120 h	no	product	
12	Cat. 3	THF	120 h	no	product	
13	Cat. 4	CH_2Cl_2	120 h	no product	trace, no detected	
14	Cat. 4	CH₃CN	120 h	no	product	
15	Cat. 4	Toluene	120 h	no	product	
16	Cat. 4	THF	120 h	no	product	
17	Cat. 5	CH_2Cl_2	120 h	no product	trace, no detected	
18	Cat. 5	CH ₃ CN	120 h	no	product	
19	Cat. 5	Toluene	120 h	no	product	
20	Cat. 5	THF	120 h	no	product	
21	Cat. 6	CH_2Cl_2	120 h	complex sys	tem, no detected	
22	Cat. 6	CH₃CN	120 h	complex system, no detected		
23	Cat. 6	Toluene	120 h	complex sys	tem, no detected	
24	Cat. 6	THF	120 h	no	product	

Further transformations reactions:

1) $Et_2O \cdot BF_3$ reduction: To a stirred solution of 4c (0.1 mmol) in CH_2Cl_2 (1.0 mL), reducing agent Et_3SiH (1.0 mmol) and $Et_2O \cdot BF_3$ (1.0 mmol) was added in one portion. Then the reaction mixture was stirred at room temperature. After completion of the

reaction (monitored by TLC), the reaction mixture was purified by flash chromatography on silica gel (EtOAc/petroleum ether) to give **5** as white solid.

2) LAH reduction: To a stirred solution of 4c (0.1 mmol) in THF (1.0 mL), reducing agent LiAlH₄ (0.15 mmol) was added in one portion. Then the reaction mixture was stirred at room temperature. After completion of the reaction (monitored by TLC, about 10 min), the reaction mixture was purified by flash chromatography on silica gel (EtOAc/petroleum ether) to give 6 as white solid.

Benzyl-7-methyl-9-phenyl-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3a)



61% yield; white solid; mp 183-186°C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 7.8 Hz, 1H), 7.66 – 7.60 (m, 1H), 7.56 (d, J = 7.0 Hz, 2H), 7.32 – 7.23 (m, 6H), 7.20 (d, J = 7.3 Hz, 2H), 7.07 (s, 2H), 5.76 (d, J = 4.6 Hz, 1H), 5.00 (s, 2H), 4.73 (d, J = 4.2 Hz, 1H), 2.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.90, 144.77, 141.41, 135.76, 133.60, 131.89, 130.30, 128.82, 128.43, 128.13, 128.11, 128.03, 127.24, 127.11, 126.85, 121.05, 120.88, 107.63, 105.67, 66.28, 41.31, 14.96; IR (neat): v 3117, 3013, 2352, 2318, 1703, 1599, 1325, 1225, 1174, 1160, 1012, 984, 851, 755 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₁NO₄S [M+H]⁺ = 444.1270, found = 444.1275.

Benzyl-7-methyl-9-(p-tolyl)-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8carboxylate 5,5-dioxide (3c)



66% yield; white solid; mp 132-133°C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 7.6 Hz, 1H), 7.65 – 7.59 (m, 1H), 7.56 (t, J = 7.2 Hz, 2H), 7.28 (d, J = 4.8 Hz, 3H), 7.08 (s, 6H), 5.75 (d, J = 4.7 Hz, 1H), 5.01 (s, 2H), 4.70 (d, J = 4.6 Hz, 1H), 2.91 (s, 3H), 2.32 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.98, 141.84, 141.04, 136.80, 135.82, 133.58, 131.86, 130.25, 129.49, 128.39, 128.15, 128.03, 128.00, 127.30, 126.75, 121.03, 120.86, 107.88, 105.82, 66.24, 40.88, 21.12, 14.96; IR (neat): v 2894, 2352, 2319, 1698, 1602, 1324, 1226, 1159, 1104, 1023, 983, 853, 755 cm⁻¹; HRMS (ESI) m/z calcd for C₂₇H₂₃NO₄S [M+H]⁺ = 458.1426, found = 458.1421.

Benzyl-9-(3,4-dimethylphenyl)-7-methyl-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3d)



95% yield; white solid; mp 146-148°C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 7.7 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.55 (t, J = 7.9 Hz, 2H), 7.27 (d, J = 7.9 Hz, 3H), 7.08 (d, J = 6.7 Hz, 2H), 7.04 (d, J = 8.1 Hz, 1H), 6.94 (s, 2H), 5.74 (d, J = 4.2 Hz, 1H), 5.08 – 4.94 (m, 2H), 4.67 (d, J = 4.2 Hz, 1H), 2.91 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 167.02, 142.26, 140.96, 136.98, 135.83, 135.45, 133.53, 131.87, 130.19, 130.08, 129.31, 128.35, 128.16, 127.97, 127.36, 126.64, 125.55, 121.01, 120.86, 107.89, 105.98, 66.24, 40.90, 19.81, 19.45, 14.95; IR (neat): v 2873, 2352, 2313, 1699, 1599, 1323, 1225, 1159, 1104, 1023, 983, 785, 745 cm⁻¹; HRMS (ESI) m/z calcd for C₂₈H₂₅NO₄S [M+H]⁺ = 472.1583, found = 472.1592.

Benzyl-9-(4-methoxyphenyl)-7-methyl-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3e)



53% yield; white solid; mp 70-72°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.8 Hz, 1H), 7.73 – 7.66 (m, 2H), 7.61 (t, J = 6.7 Hz, 1H), 7.43 – 7.29 (m, 5H), 7.16 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 6.33 (s, 1H), 5.99 (d, J = 3.7 Hz, 1H), 5.13 (q, J = 12.4 Hz, 2H), 3.79 (d, J = 6.7 Hz, 5H), 3.31 (dd, J = 16.6, 9.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.25, 158.79, 146.11, 136.16, 134.13, 133.79, 131.46, 130.45, 129.09, 128.53, 128.42, 128.25, 128.11, 127.97, 121.37, 121.13, 114.31, 106.54, 100.67, 65.90, 55.34, 36.44, 31.74; IR (neat): v 2916, 2848, 2352, 2312, 1700, 1325, 1317, 1248, 1160, 1105, 1023, 982, 785, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₇H₂₃NO₅S [M+H]⁺ = 474.1375, found = 474.1357.

Benzyl-7-methyl-9-(3,4,5-trimethoxyphenyl)-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3g)



43% yield; white solid; mp 135-138°C; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 7.2 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.63 – 7.55 (m, 2H), 7.28 (dd, *J* = 8.7, 2.6 Hz, 3H), 7.09 (d, *J* = 2.1 Hz, 2H), 6.38 (d, *J* = 2.2 Hz, 2H), 5.81 – 5.71 (m, 1H), 5.03 (dd, *J* = 28.9, 12.4 Hz, 2H), 4.69 (s, 1H), 3.83 (d, *J* = 2.3 Hz, 3H), 3.71 (d, *J* = 2.2 Hz, 6H), 2.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.93, 153.47, 141.32, 140.57, 136.90, 135.68, 133.65, 131.91, 130.35, 128.42, 128.14, 128.08, 127.25, 126.78, 121.07, 120.91, 107.50, 105.69, 104.73, 66.37, 60.84, 56.04, 41.66, 14.94. IR (neat): 2907, 2850, 2352, 1700, 1324, 1315, 1249, 1158, 1105, 1023, 982, 794, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₉H₂₇NO₇S [M+Na]+ = 556.1405, found = 556.1408.

Benzyl-9-(2-fluorophenyl)-7-methyl-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3h)



63% yield; white solid; mp 144-145°C; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, J = 7.6 Hz, 1H), 7.66 – 7.53 (m, 3H), 7.29 – 7.16 (m, 5H), 7.12 – 6.91 (m, 4H), 5.78 (d, J = 4.6 Hz, 1H), 5.14 (d, J = 4.3 Hz, 1H), 5.01 (q, J = 12.4 Hz, 2H), 2.98 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.57, 143.35, 135.73, 133.65, 131.80, 131.72, 131.58, 130.39, 129.76, 129.72, 128.59, 128.51, 128.38, 127.95, 127.46, 127.10, 124.81, 121.04, 120.93, 115.54, 115.32, 105.55, 104.14, 66.24, 33.98, 14.97; IR (neat): v 2895, 2352, 2318, 1698, 1324, 1252, 1158, 1105, 1022, 982, 893, 754 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₀FNO₄S [M+H]⁺ = 462.1175, found = 462.1157.

Benzyl-9-(4-chlorophenyl)-7-methyl-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3i)



58% yield; white solid; mp 174-175°C; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J = 7.7 Hz, 1H), 7.68 – 7.61 (m, 1H), 7.58 (t, J = 7.6 Hz, 2H), 7.29 (d, J = 5.0 Hz, 3H), 7.20 (d, J = 7.3 Hz, 2H), 7.09 (dd, J = 11.3, 6.3 Hz, 4H), 5.70 (d, J = 4.0 Hz, 1H), 5.02 (dd, J = 28.8, 12.2 Hz, 2H), 4.70 (d, J = 4.3 Hz, 1H), 2.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.68, 143.32, 141.68, 135.60, 133.70, 132.88, 131.90, 130.48, 129.43, 128.90, 128.46, 128.26, 128.18, 127.10, 127.06, 121.10, 120.88, 107.25, 104.96, 66.35, 40.78, 14.97; IR (neat): v 2895, 2352, 2318, 1700, 1324, 1252, 1159, 1104, 1022, 982, 893, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₀ClNO₄S [M+H]⁺ = 478.0880, found = 478.0874.

Benzyl-9-(4-bromophenyl)-7-methyl-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8carboxylate 5,5-dioxide (3k)



74% yield; white solid; mp 171-172°C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 7.6 Hz, 1H), 7.67 – 7.61 (m, 1H), 7.58 (t, J = 8.0 Hz, 2H), 7.35 (d, J = 7.5 Hz, 2H), 7.32 – 7.26 (m, 3H), 7.05 (t, J = 7.1 Hz, 4H), 5.70 (d, J = 4.4 Hz, 1H), 5.02 (dd, J = 32.7, 12.2 Hz, 2H), 4.69 (d, J = 4.1 Hz, 1H), 2.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.66, 143.84, 141.76, 135.59, 133.72, 131.86, 130.49, 129.80, 129.69, 128.48, 128.26, 128.19, 127.11, 127.04, 121.10, 121.01, 120.88, 107.14, 104.88, 66.36, 40.87, 14.97; IR (neat): v 2895, 2352, 2318, 1699, 1324, 1252, 1159, 1104, 1023, 983, 893, 753 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₀BrNO₄S [M+H]⁺ = 522.0375, found = 522.0356.

Benzyl-7-methyl-9-(naphthalen-1-yl)-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8carboxylate 5,5-dioxide (3n)



62% yield; white solid; mp 146-148°C; ¹H NMR (400 MHz, CDCl₃) δ 8.19 – 8.09 (m, 1H), 7.95 – 7.86 (m, 1H), 7.80 (d, J = 7.3 Hz, 1H), 7.74 (d, J = 6.4 Hz, 1H), 7.62 – 7.37 (m, 7H), 7.10 (t, J = 7.2 Hz, 1H), 6.97 (t, J = 7.3 Hz, 2H), 6.62 (d, J = 7.3 Hz, 2H), 5.86 (d, J = 4.4 Hz, 1H), 5.65 (s, 1H), 4.95 – 4.73 (m, 2H), 3.04 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.86, 135.34, 133.96, 133.54, 131.80, 130.23, 129.03,

128.10, 127.70, 127.51, 127.28, 126.77, 126.60, 126.48, 126.20, 125.79, 122.50, 121.01, 120.87, 107.06, 105.15, 66.18, 14.85; IR (neat): v 2895, 2352, 2313, 1703, 1324, 1249, 1160, 1105, 1022, 983, 893, 743 cm⁻¹; HRMS (ESI) m/z calcd for $C_{30}H_{23}NO_4S [M+H]^+ = 494.1426$, found = 494.1426.

Benzyl-7-methyl-9-(naphthalen-2-yl)-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8carboxylate 5,5-dioxide (30)



55% yield; white solid; mp 168-170°C; ¹H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 28.4, 8.7 Hz, 4H), 7.60 (t, J = 11.4 Hz, 4H), 7.47 (s, 2H), 7.36 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 6.6 Hz, 1H), 7.11 (t, J = 6.7 Hz, 2H), 6.96 (d, J = 6.8 Hz, 2H), 5.80 (s, 1H), 4.96 (s, 2H), 4.91 (s, 1H), 2.97 (s, 3H). ¹³C NMR (101 MHz, CDCl3) δ 166.90, 142.05, 141.50, 135.60, 133.62, 133.52, 132.62, 131.93, 130.34, 128.70, 128.29, 128.12, 127.98, 127.96, 127.65, 127.24, 126.93, 126.73, 126.27, 126.19, 125.86, 121.07, 120.87, 107.56, 105.46, 66.34, 41.54, 14.98. IR (neat): v 2896, 2352, 2313, 1700, 1324, 1250, 1160, 1105, 1022, 987, 893, 745 cm⁻¹; HRMS (ESI) m/z calcd for C₃₀H₂₃NO₄S [M+H]⁺ = 494.1426, found = 494.1415.

Benzyl-7-methyl-9-(thiophen-2-yl)-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8carboxylate 5,5-dioxide (3p)



33% yield; white solid; mp 180-182°C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 7.6 Hz, 1H), 7.70 – 7.54 (m, 3H), 7.31 (s, 3H), 7.23 – 7.08 (m, 3H), 6.90 (s, 1H), 6.82 (s, 1H), 5.84 (d, J = 4.8 Hz, 1H), 5.21 – 5.00 (m, 3H), 2.90 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.74, 148.80, 141.13, 135.81, 133.72, 131.94, 130.46, 128.50, 128.19, 128.12, 127.32, 127.12, 127.06, 124.82, 124.78, 121.10, 120.96, 107.43, 104.46, 66.40, 35.78, 14.94; IR (neat): v 2914, 2873, 2380, 2312, 1699, 1325, 1247, 1159, 1103, 1022, 982, 893, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₄H₁₉NO₄S₂ [M+H]⁺ = 450.0834, found = 450.0812.

Benzyl-9-(benzo[d][1,3]dioxol-5-yl)-7-methyl-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3r)



71% yield; white solid; mp 161-163°C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 7.7 Hz, 1H), 7.69 – 7.50 (m, 3H), 7.30 (s, 3H), 7.14 (s, 2H), 6.66 (dd, J = 18.0, 9.3 Hz, 3H), 5.92 (s, 2H), 5.72 (d, J = 4.6 Hz, 1H), 5.04 (q, J = 12.3 Hz, 2H), 4.64 (d, J = 4.3 Hz, 1H), 2.90 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.92, 147.93, 146.64, 140.91, 138.86, 135.76, 133.62, 131.89, 130.31, 128.43, 128.28, 128.10, 127.25, 126.79, 121.31, 121.06, 120.85, 108.63, 108.40, 107.86, 105.54, 101.08, 66.31, 40.94, 14.92; IR (neat): v 2917, 2849, 2352, 2318, 1698, 1323, 1247, 1159, 1104, 1023, 982, 893, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₇H₂₁NO₆S [M+H]⁺ = 488.1168, found = 488.1155.

Ethyl-7-methyl-9-(p-tolyl)-9H-benzo[4,5]isothiazolo[2,3-a]pyridine-8-carboxylate 5,5-dioxide (3t)



53% yield; white solid; mp 139-140°C; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J = 8.1 Hz, 1H), 7.67 – 7.61 (m, 1H), 7.60 – 7.52 (m, 2H), 7.13 (dd, J = 17.5, 7.9 Hz, 4H), 5.76 (d, J = 4.7 Hz, 1H), 4.69 (d, J = 4.2 Hz, 1H), 4.03 (q, J = 7.1 Hz, 2H), 2.89 (s, 3H), 2.31 (s, 3H), 1.11 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 167.16, 141.92, 140.20, 136.80, 133.54, 131.95, 130.21, 129.41, 128.06, 127.38, 126.86, 121.03, 120.84, 108.42, 105.74, 60.33, 40.99, 21.09, 14.84, 14.00; IR (neat): v 2946, 2912, 2352, 2319, 1698, 1350, 1267, 1158, 1105, 1023, 983, 893, 785, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₂H₂₁NO₄S [M+H]⁺ = 396.1270, found = 396.1239.

Benzyl-(E)-2-(5,5-dioxido-9-phenyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4a)



50% yield; white solid; mp 119-120°C; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 7.7 Hz, 1H), 7.75 – 7.66 (m, 2H), 7.61 (t, J = 6.3 Hz, 1H), 7.35 (dd, J = 9.9, 5.8 Hz, 6H), 7.27 (dd, J = 14.7, 7.1 Hz, 4H), 6.34 (s, 1H), 6.01 (d, J = 3.7 Hz, 1H), 5.13 (q, J = 12.4 Hz, 2H), 3.87 (ddd, J = 12.6, 11.7, 4.9 Hz, 2H), 3.27 (dd, J = 14.7, 8.3 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.24, 146.01, 142.14, 136.13, 133.81, 131.47, 130.50, 129.28, 128.97, 128.53, 128.26, 128.12, 127.92, 127.42, 127.35, 121.39, 121.14, 106.18, 100.67, 65.93, 37.26, 31.59; IR (neat): v 3029, 1708, 1672, 1620, 1494, 1471, 1453, 1394, 1327, 1248, 1183, 1162, 1130, 824, 754, 743 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₁NO₄S [M+H]⁺ = 444.1270, found = 444.1255.

Benzyl-(E)-2-(5,5-dioxido-9-(o-tolyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4b)



82% yield; white solid; mp 70-73°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.8 Hz, 1H), 7.69 (s, 2H), 7.60 (t, J = 6.5 Hz, 1H), 7.39 – 7.29 (m, 5H), 7.14 (s, 4H), 6.33 (s, 1H), 5.99 (d, J = 3.7 Hz, 1H), 5.13 (q, J = 12.4 Hz, 2H), 3.93 – 3.71 (m, 2H), 3.27 (dd, J = 14.6, 8.1 Hz, 1H), 2.34 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.24, 146.13, 139.10, 136.99, 136.17, 133.78, 131.46, 130.43, 129.70, 129.62, 129.13, 128.52, 128.35, 128.25, 128.10, 127.97, 127.27, 121.36, 121.13, 106.48, 100.63, 65.89, 36.84, 31.62, 21.09; IR (neat): v 3065, 3030, 2952, 1708, 1620, 1492, 1470, 1455, 1394, 1326, 1244, 1183, 1162, 1130, 833, 754, 743 cm⁻¹; HRMS (ESI) m/z calcd for C₂₇H₂₃NO₄S [M+H]⁺ = 458.1426, found = 458.1409.

Benzyl-(E)-2-(5,5-dioxido-9-(p-tolyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4c)



66% yield; white solid; mp 146-148°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.8 Hz, 1H), 7.75 – 7.64 (m, 2H), 7.64 – 7.55 (m, 1H), 7.50 – 7.27 (m, 5H), 7.14 (s, 4H), 6.33 (s, 1H), 5.99 (d, J = 2.8 Hz, 1H), 5.13 (q, J = 12.5 Hz, 2H), 3.97 – 3.68 (m, 2H), 3.27 (dd, J = 14.6, 8.0 Hz, 1H), 2.34 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.24,

146.12, 139.09, 136.97, 136.15, 133.78, 131.45, 130.43, 129.61, 129.13, 128.52, 128.25, 128.10, 127.97, 127.26, 121.36, 121.12, 106.48, 100.62, 65.89, 36.84, 31.61, 21.09; IR (neat): v 3063, 3030, 2321, 1708, 1620, 1513, 1471, 1454, 1394, 1327, 1249, 1183, 1162, 1129, 834, 754 cm⁻¹; HRMS (ESI) m/z calcd for $C_{27}H_{23}NO_4S$ [M+H]⁺ =458.1426, found =458.1403.

Benzyl-(E)-2-(9-(3,4-dimethylphenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4d)



66% yield; white solid; mp 152-154°C; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 4.9 Hz, 2H), 7.60 (t, J = 6.8 Hz, 1H), 7.34 (dd, J = 15.6, 6.6 Hz, 5H), 7.10 (d, J = 7.6 Hz, 1H), 6.98 (t, 2H), 6.34 (s, 1H), 5.98 (d, J = 3.6 Hz, 1H), 5.21 – 5.06 (m, 2H), 3.93 (dd, J = 15.3, 5.7 Hz, 1H), 3.76 (dd, J = 8.8, 4.7 Hz, 1H), 3.18 (dd, J = 15.2, 9.2 Hz, 1H), 2.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 166.26, 146.30, 139.62, 137.16, 136.18, 135.64, 133.78, 131.43, 130.41, 130.16, 129.05, 128.69, 128.53, 128.27, 128.11, 128.00, 124.69, 121.35, 121.14, 106.76, 100.48, 65.89, 36.85, 31.67, 19.88, 19.44; IR (neat): v 3064, 3032, 1708, 1673, 1620, 1501, 1471, 1453, 1394, 1327, 1291, 1255, 1183, 1163, 1130, 833, 755 cm⁻¹; HRMS (ESI) m/z calcd for C₂₈H₂₅NO₄S [M+H]⁺=472.1583, found =472.1560.

Benzyl-(E)-2-(9-(4-methoxyphenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4e)



57% yield; white solid; mp 122-123°C; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 7.8 Hz, 1H), 7.73 – 7.64 (m, 2H), 7.60 (t, J = 6.9 Hz, 1H), 7.45 – 7.27 (m, 5H), 7.15 (d, J = 7.6 Hz, 2H), 6.86 (d, J = 7.6 Hz, 2H), 6.34 (s, 1H), 5.98 (s, 1H), 5.20 – 5.02 (m, 2H), 3.79 (s, 5H), 3.31 (dd, J = 16.5, 10.0 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.24, 158.79, 146.12, 136.16, 134.13, 133.79, 131.46, 130.45, 129.09, 128.53, 128.41, 128.25, 128.11, 127.97, 121.36, 121.13, 114.31, 106.54, 100.66, 100.00, 65.89, 55.34, 36.43, 31.74; IR (neat): v 3064, 3011, 1708, 1673, 1619, 1511, 1470, 1455, 1394,

1327, 1249, 1183, 1162, 1140, 832, 755 cm⁻¹; HRMS (ESI) m/z calcd for $C_{27}H_{23}NO_5S$ [M+H]⁺ =474.1375, found =474.1356.

Benzyl-(E)-2-(9-(2,4-dimethoxyphenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4f)



77% yield; white solid; mp 71-73°C; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 6.1 Hz, 1H), 7.69 (s, 2H), 7.59 (s, 1H), 7.36 (s, 5H), 7.03 (d, J = 7.2 Hz, 1H), 6.52 – 6.38 (m, 2H), 6.32 (s, 1H), 5.98 (s, 1H), 5.13 (s, 2H), 4.16 (s, 1H), 3.81 (d, J = 8.8 Hz, 6H), 3.65 – 3.41 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 166.32, 160.02, 157.78, 146.89, 136.27, 133.68, 131.29, 130.18, 128.93, 128.50, 128.26, 128.20, 128.16, 128.04, 122.28, 121.30, 121.05, 106.86, 104.17, 100.05, 98.85, 65.79, 55.45, 55.42, 30.26, 29.79; IR (neat): v 2955, 2836, 2351, 2322, 1709, 1677, 1614, 1586, 1504, 1468, 1455, 1438, 1418, 1395, 1326, 1292, 1263, 1208, 1183, 1161, 1129, 833, 755 cm⁻¹; HRMS (ESI) m/z calcd for C₂₈H₂₅NO₆S [M+H]⁺=504.1481, found =504.1462.

Benzyl-(E)-2-(9-(2-fluorophenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4h)



70% yield; white solid; mp 132-133°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.8 Hz, 1H), 7.69 (q, J = 7.7 Hz, 2H), 7.61 (t, J = 7.2 Hz, 1H), 7.45 – 7.27 (m, 5H), 7.22 (dd, J = 17.2, 9.3 Hz, 2H), 7.08 (dd, J = 18.8, 8.6 Hz, 2H), 6.35 (s, 1H), 5.98 (d, J = 4.2 Hz, 1H), 5.22 – 5.04 (m, 2H), 4.18 (dd, J = 11.7, 6.2 Hz, 1H), 3.75 (dd, J = 15.4, 5.9 Hz, 1H), 3.48 (dd, J = 15.4, 8.0 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.20, 161.68, 159.24, 145.76, 136.10, 133.86, 131.39, 130.58, 129.60, 129.02, 128.94, 128.75, 128.55, 128.29, 128.15, 127.83, 124.64, 121.37, 121.20, 115.86, 115.64, 104.84, 100.79, 65.98, 30.26, 29.70; IR (neat): v 3065, 3032, 2892, 2351, 1709, 1679, 1621, 1584, 1490, 1472, 1454, 1395, 1328, 1229, 1183, 1162, 1140, 834, 754 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₀FNO₄S [M+H]⁺=462.1175, found =462.1161.

Benzyl-(E)-2-(9-(4-chlorophenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4i)



59% yield; white solid; mp 152-154°C; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 7.8 Hz, 1H), 7.76 – 7.67 (m, 2H), 7.63 (dd, J = 9.5, 3.8 Hz, 1H), 7.32 (dt, J = 21.8, 8.6 Hz, 7H), 7.17 (d, J = 8.2 Hz, 2H), 6.34 (s, 1H), 5.96 (d, J = 4.0 Hz, 1H), 5.23 – 5.02 (m, 2H), 3.79 (ddd, J = 20.8, 14.1, 5.8 Hz, 2H), 3.36 (dd, J = 15.0, 7.8 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.19, 145.49, 140.53, 136.05, 133.87, 133.12, 130.66, 129.57, 129.09, 128.78, 128.55, 128.26, 128.17, 127.75, 121.42, 121.18, 105.21, 101.06, 99.99, 65.99, 36.62, 31.40; IR (neat): v 3080, 2892, 2351, 2322, 1709, 1679, 1621, 1553, 1492, 1471, 1454, 1434, 1395, 1327, 1229, 1183, 1162, 1141, 832, 754 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₀CINO₄S [M+H]⁺ =478.0880, found =478.0864.

Benzyl-(E)-2-(9-(2,4-dichlorophenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4j)



68% yield; white solid; mp 82-84°C; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 7.6 Hz, 1H), 7.77 – 7.68 (m, 2H), 7.67 – 7.59 (m, 1H), 7.43 (s, 1H), 7.36 (s, 5H), 7.21 (d, J = 8.1 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H), 6.35 (s, 1H), 5.94 (d, J = 4.0 Hz, 1H), 5.22 – 5.04 (m, 2H), 4.31 (d, J = 5.0 Hz, 1H), 3.59 (ddd, J = 32.5, 15.4, 6.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 166.05, 145.06, 137.64, 135.99, 134.14, 133.92, 133.66, 131.44, 130.76, 130.13, 129.74, 129.22, 128.54, 128.31, 128.18, 127.72, 127.64, 121.43, 121.23, 103.82, 101.35, 66.04, 33.24, 29.42; IR (neat): v 3080, 2892, 2352, 2321, 1710, 1679, 1621, 1554, 1471, 1380, 1329, 1264, 1184, 1162, 1141, 833, 754 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₁₉Cl₂NO₄S [M+H]⁺ = 512.0466, found = 512.0476.

Benzyl-(E)-2-(9-(4-bromophenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4k)



53% yield; white solid; mp 139-141°C; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 7.8 Hz, 1H), 7.75 – 7.66 (m, 2H), 7.63 (dd, J = 9.5, 4.0 Hz, 1H), 7.45 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 39.2 Hz, 5H), 7.12 (d, J = 8.3 Hz, 2H), 6.34 (s, 1H), 5.95 (d, J = 3.7 Hz, 1H), 5.22 – 5.01 (m, 2H), 3.77 (dd, J = 23.7, 8.7 Hz, 2H), 3.36 (dd, J = 14.7, 7.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.17, 145.45, 141.06, 136.05, 133.87, 132.04, 131.51, 130.67, 129.60, 129.14, 128.55, 128.26, 128.16, 127.73, 121.41, 121.18, 105.09, 101.08, 100.00, 65.99, 36.68, 31.32; IR (neat): v 3080, 3031, 2890, 2321, 1708, 1674, 1621, 1487, 1472, 1454, 1398, 1264, 1184, 1162, 1140, 824, 754 cm⁻¹; HRMS (ESI) m/z calcd for C₂₆H₂₀BrNO₄S [M+H]⁺=522.0375, found =522.0365.

Benzyl-(E)-2-(9-(4-cyanophenyl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4l)



41% yield; white solid; mp 70-72°C; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 7.7 Hz, 1H), 7.73 (d, J = 2.7 Hz, 2H), 7.65 (dd, J = 14.5, 5.3 Hz, 3H), 7.36 (s, 7H), 6.35 (s, 1H), 5.95 (d, J = 4.0 Hz, 1H), 5.20 – 5.06 (m, 2H), 3.91 (d, J = 5.5 Hz, 1H), 3.72 (dd, J = 15.2, 5.6 Hz, 1H), 3.48 (dd, J = 15.3, 7.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.11, 147.40, 144.84, 135.94, 133.96, 132.79, 131.58, 130.91, 130.11, 128.56, 128.28, 128.24, 127.52, 121.48, 121.24, 118.63, 111.34, 103.68, 101.47, 66.07, 37.18, 30.93; IR (neat): v 2352, 2312, 2228, 1842, 1731, 1699, 1553, 1329, 1262, 1183, 1162, 1141, 821, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₇H₂₀N₂O₄S [M+H]⁺ =469.1222, found =469.1205.

Benzyl-(E)-2-(5,5-dioxido-9-((E)-styryl)-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4m)



60% yield; white solid; mp 72-75°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.4 Hz, 1H), 7.77 – 7.67 (m, 2H), 7.64 – 7.58 (m, 1H), 7.49 – 7.27 (m, 10H), 6.53 (d, J = 15.9 Hz, 1H), 6.36 (s, 1H), 6.15 (dd, J = 15.9, 6.8 Hz, 1H), 5.92 (s, 1H), 5.34 – 5.06 (m, 2H), 3.60 – 3.51 (m, 1H), 3.51 – 3.38 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 166.37, 145.99, 136.66, 136.15, 133.77, 131.41, 130.46, 129.08, 129.02, 128.61, 128.53, 128.29, 128.12, 127.93, 127.71, 127.08, 126.39, 121.37, 121.10, 104.95, 100.97, 65.97, 34.44, 29.33; IR (neat): v 3080, 3030, 2943, 2321, 1708, 1619, 1495, 1471, 1453, 1394, 1264, 1183, 1163, 1141, 842, 753 cm⁻¹; HRMS (ESI) m/z calcd for C₂₈H₂₃NO₄S [M+H]⁺ =470.1426, found =470.1428.

Benzyl-(E)-2-(9-(naphthalen-1-yl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4n)



88% yield; white solid; mp 82-85°C; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, J = 8.2 Hz, 1H), 7.90 (dd, J = 14.8, 7.9 Hz, 2H), 7.80 (d, J = 7.9 Hz, 1H), 7.70 (q, J = 8.0 Hz, 2H), 7.58 (ddd, J = 19.5, 14.6, 7.1 Hz, 3H), 7.48 – 7.37 (m, 2H), 7.29 (d, J = 27.9 Hz, 5H), 6.37 (s, 1H), 6.11 (d, J = 3.7 Hz, 1H), 5.09 (q, J = 12.4 Hz, 2H), 4.80 – 4.51 (m, 1H), 4.13 (dd, J = 15.2, 5.6 Hz, 1H), 3.42 (dd, J = 15.1, 9.1 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.14, 146.17, 137.50, 136.09, 134.12, 133.82, 131.46, 130.95, 130.49, 129.50, 129.26, 128.50, 128.27, 128.10, 128.06, 127.94, 126.66, 125.88, 125.63, 124.51, 122.77, 121.41, 121.19, 106.48, 100.73, 65.93, 33.05, 30.51; IR (neat): v 3079, 2974, 2352, 2313, 1708, 1620, 1515, 1471, 1454, 1395, 1264, 1183, 1161, 1141, 833, 754 cm⁻¹; HRMS (ESI) m/z calcd for C₃₀H₂₃ClNO₄S [M+H]⁺ =494.1426, found =494.1420.

Benzyl-(E)-2-(9-(naphthalen-2-yl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (40)



81% yield; white solid; mp 155-147°C; ¹H NMR (400 MHz, CDCl₃) δ 7.93 – 7.76 (m, 4H), 7.72 (dd, J = 14.0, 8.0 Hz, 3H), 7.61 (t, J = 7.4 Hz, 1H), 7.53 – 7.42 (m, 2H), 7.42 – 7.21 (m, 6H), 6.36 (s, 1H), 6.07 (d, J = 3.0 Hz, 1H), 5.11 (q, J = 12.4 Hz, 2H), 4.09 – 3.84 (m, 2H), 3.41 (dd, J = 14.8, 8.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.23, 145.95, 139.46, 136.11, 133.84, 133.51, 132.65, 131.52, 130.55, 129.45, 128.85, 128.51, 128.25, 128.11, 127.92, 127.81, 127.70, 126.37, 126.00, 125.96, 125.59, 121.40, 121.22, 105.94, 100.84, 65.93, 37.37, 31.51; IR (neat): v 3079, 2352, 2320, 1708, 1620, 1537, 1471, 1454, 1395, 1265, 1183, 1162, 1141, 841, 752 cm⁻¹; HRMS (ESI) m/z calcd for C₃₀H₂₃NO₄S [M+H]⁺=494.1426, found =494.1419.

Benzyl-(E)-2-(5,5-dioxido-9-(thiophen-2-yl)-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4p)



57% yield; white solid; mp 53-56°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.7 Hz, 1H), 7.75 – 7.66 (m, 2H), 7.62 (t, J = 6.8 Hz, 1H), 7.36 (d, J = 12.3 Hz, 5H), 7.20 (d, J = 4.4 Hz, 1H), 6.95 (d, J = 8.1 Hz, 2H), 6.36 (s, 1H), 6.05 (d, J = 3.6 Hz, 1H), 5.16 (q, J = 12.4 Hz, 2H), 4.14 (d, J = 5.1 Hz, 1H), 3.74 (dd, J = 15.1, 5.3 Hz, 1H), 3.62 (dd, J = 15.0, 7.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.21, 145.39, 145.03, 136.10, 133.86, 131.54, 130.66, 129.05, 128.55, 128.28, 128.14, 127.77, 127.08, 124.51, 124.38, 121.38, 121.26, 105.41, 101.30, 65.99, 32.43, 31.63; IR (neat): v 2920, 2850, 2352, 2320, 1710, 1622, 1537, 1470, 1454, 1395, 1265, 1184, 1162, 1142, 745 cm⁻¹; HRMS (ESI) m/z calcd for C₂₄H₁₉NO₄S₂ [M+H]⁺ =450.0834, found =450.0832.

Benzyl-(E)-2-(9-(furan-2-yl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4q)



49% yield; white solid; mp 63-65°C; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 7.7 Hz, 1H), 7.71 (t, J = 8.3 Hz, 2H), 7.61 (t, J = 7.2 Hz, 1H), 7.43 – 7.32 (m, 6H), 6.40 – 6.27 (m, 2H), 6.15 (s, 1H), 6.03 (d, J = 4.0 Hz, 1H), 5.24 – 5.10 (m, 2H), 3.94 (dd, J = 11.4, 5.7 Hz, 1H), 3.76 (dd, J = 15.3, 5.5 Hz, 1H), 3.56 (dd, J = 15.3, 8.1 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.27, 154.05, 145.58, 142.07, 136.12, 133.81, 131.47, 130.60, 129.35, 128.55, 128.29, 128.15, 127.81, 121.35, 121.23, 110.41, 105.65, 102.93, 100.99, 66.00, 30.86, 28.09; IR (neat): v 2962, 2894, 2352, 2320, 1711, 1622, 1537, 1471, 1454, 1395, 1263, 1184, 1162, 1141, 744 cm⁻¹; HRMS (ESI) m/z calcd for C₂₄H₁₉NO₅S [M+H]⁺=434.1062, found =434.1068.

Benzyl-(E)-2-(9-(benzo[d][1,3]dioxol-5-yl)-5,5-dioxido-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4r)



82% yield; white solid; mp 72-74°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 13.4 Hz, 2H), 7.61 (t, J = 6.3 Hz, 1H), 7.45 – 7.28 (m, 5H), 6.88 – 6.60 (m, 3H), 6.34 (s, 1H), 5.95 (s, 3H), 5.14 (q, J = 12.5 Hz, 2H), 3.79 (dd, J = 22.9, 8.4 Hz, 2H), 3.28 (dd, J = 13.9, 7.1 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.24, 148.04, 146.77, 145.92, 136.13, 135.94, 133.82, 131.47, 130.52, 129.23, 128.53, 128.27, 128.13, 127.88, 121.38, 121.14, 120.53, 108.56, 107.81, 106.12, 101.14, 100.75, 65.93, 36.95, 31.80; IR (neat): v 2918, 2849, 2352, 2319, 1711, 1621, 1537, 1471, 1453, 1396, 1264, 1183, 1161, 1142, 745 cm⁻¹; HRMS (ESI) m/z calcd for C₂₇H₂₁NO₆S [M+H]⁺ =488.1168, found =488.1171.

Methyl-(E)-2-(5,5-dioxido-9-(p-tolyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4s)



53% yield; white solid; mp 149-150°C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 7.7 Hz, 1H), 7.68 (d, J = 12.9 Hz, 2H), 7.60 (t, J = 6.8 Hz, 1H), 7.14 (s, 4H), 6.30 (s, 1H), 5.98 (s, 1H), 3.85 – 3.75 (m, 2H), 3.68 (s, 3H), 3.28 (dd, J = 17.1, 10.2 Hz, 1H), 2.33 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.85, 145.79, 139.11, 136.97, 133.79, 131.45, 130.45, 129.61, 129.12, 127.98, 127.26, 121.34, 121.14, 106.41, 100.61, 51.22, 36.84, 31.56, 21.09; IR (neat): v 2948, 2352, 2314, 1710, 1622, 1533, 1471, 1454, 1385, 1266, 1187, 1162, 1145, 755 cm⁻¹; HRMS (ESI) m/z calcd for C₂₁H₁₉NO₄S [M+H]⁺ = 382.1113, found = 382.1116.

Ethyl-(E)-2-(5,5-dioxido-9-(p-tolyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-ylidene)acetate (4t)



59% yield; white solid; mp 108-110°C; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 6.5 Hz, 1H), 7.69 (s, 2H), 7.60 (s, 1H), 7.14 (s, 4H), 6.29 (s, 1H), 5.98 (s, 1H), 4.13 (s, 2H), 3.82 (d, J = 14.8 Hz, 2H), 3.27 (s, 1H), 2.33 (s, 3H), 1.26 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.44, 145.55, 139.17, 136.93, 133.78, 131.46, 130.43, 129.60, 129.14, 128.00, 127.27, 121.33, 121.15, 106.41, 101.12, 59.99, 36.86, 31.53, 21.09, 14.29; IR (neat): v 2953, 2873, 2352, 2313, 1703, 1622, 1553, 1471, 1454, 1383, 1266, 1185, 1162, 1144, 754 cm⁻¹; HRMS (ESI) m/z calcd for C₂₂H₂₁NO₄S [M+H]⁺ = 396.1270, found = 396.1277.

Benzyl-2-(5,5-dioxido-9-(p-tolyl)-8,9,10,10a-tetrahydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridin-7-yl)acetate (5)



92% yield; white solid; mp 64-66°C; ¹H NMR (400 MHz, CDCl₃) δ 7.77 (d, J = 7.2 Hz, 1H), 7.54 (dt, J = 27.8, 7.1 Hz, 2H), 7.34 (s, 6H), 7.11 (d, J = 8.6 Hz, 4H), 5.14 (q, J = 12.1 Hz, 2H), 4.39 (d, J = 11.0 Hz, 1H), 3.96 (s, 1H), 3.67 (d, J = 15.8 Hz, 1H), 3.07 – 2.82 (m, 2H), 2.42 (d, J = 12.2 Hz, 1H), 2.32 (s, 3H), 2.09 (d, J = 12.3 Hz, 1H), 1.75 (dt, J = 23.3, 11.8 Hz, 2H).¹³C NMR (101 MHz, CDCl₃) δ 170.30, 140.85, 137.61, 136.59, 135.61, 132.87, 129.63, 129.43, 129.29, 128.60, 128.34, 127.29,

126.73, 122.75, 121.18, 66.69, 61.01, 53.73, 41.58, 38.28, 37.09, 36.94, 21.04; IR (neat): v 3032, 2919, 2850, 2375, 2310, 1735, 1658, 1514, 1470, 1294, 1170, 1060, 967, 815, 748 cm⁻¹; HRMS (ESI) m/z calcd for $C_{27}H_{27}NO_4S$ [M+H]⁺ = 462.1739, found = 462.1735.

(E)-7-(2-hydroxyethylidene)-9-(p-tolyl)-8,9-dihydro-7Hbenzo[4,5]isothiazolo[2,3-a]pyridine 5,5-dioxide (6)

53% yield; white solid; mp 125-128°C; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 7.7 Hz, 1H), 7.66 (q, J = 7.8 Hz, 2H), 7.62 – 7.55 (m, 1H), 7.19 – 7.07 (m, 4H), 6.23 (t, J = 7.2 Hz, 1H), 5.83 (d, J = 3.4 Hz, 1H), 4.12 (dd, J = 17.6, 7.2 Hz, 2H), 3.79 (d, J = 4.8 Hz, 1H), 2.89 (dd, J = 13.8, 4.9 Hz, 1H), 2.64 (dd, J = 13.8, 7.1 Hz, 1H), 2.33 (s, 3H), 1.13 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 139.72, 137.01, 133.31, 132.01, 131.95, 130.25, 130.21, 129.54, 128.45, 127.37, 121.21, 121.06, 112.37, 103.68, 57.68, 38.06, 32.07, 21.06; IR (neat): v 3059, 3021, 2922, 2860, 2378, 2319, 1711, 1672, 1513, 1470, 1316, 1275, 1175, 1158, 1132, 817, 751 cm⁻¹; HRMS (ESI) m/z calcd for C₂₀H₁₉NO₃S [M+H]⁺ = 354.1164, found = 354.1153.



100 90 fl (ppm)



100 90 fl (ppm)













---0.00



S26











-2.92 -1.57





















100 90 fl (ppm)











S33

















































































100 90 fl (ppm)







100 90 fl (ppm)













-0.00

















100 90 fl (ppm)

























Ch1 210nm	
	Ch1 210nm

Bettettor IT entr 210mm							
Peak#	Ret. Time	Area	Height	Area %	Height %		
1	49.077	28915204	230905	49.658	54.742		
2	56.070	29313431	190905	50.342	45.258		
Total		58228635	421810	100.000	100.000		

The racemic system of **3c**, determined by HPLC (Chiralpak OD-H, hexane/2-propanol = 99/1; flow rate 1.0 mL/min; 25°C; λ = 210 nm)



D	Detector A Ch1 210nm							
	Peak#	Ret. Time	Area	Height	Area %	Height %		
	1	49.738	16782464	133841	62.606	66.730		
Γ	2	57.218	10024163	66729	37.394	33.270		
	Total		26806627	200570	100.000	100.000		

The asymmetric system of **3c** with the chiral **cat.1** (β -ICD) in CH₂Cl₂, enantiomeric excess: 25%, determined by HPLC (Chiralpak OD-H, hexane/2-propanol = 99/1; flow rate 1.0 mL/min; 25°C; λ = 210 nm)



Detector	A	Ch1	21	0nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	49.190	30999490	245876	50.567	55.396
2	56.316	30303842	197978	49.433	44.604
Total		61303332	443854	100.000	100.000

The asymmetric system of **3c** with the chiral **cat.1** (β -ICD) in toluene, enantiomeric excess: 1%, determined by HPLC (Chiralpak OD-H, hexane/2-propanol = 99/1; flow rate 1.0 mL/min; 25°C; λ = 210 nm)



Detector A Ch1 210nm								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	13.744	17242480	752692	49.226	69.234			
2	25.981	17784567	334478	50.774	30.766			
Total		35027046	1087170	100.000	100.000			

The racemic system of **4c**, determined by HPLC (Chiralpak IA, hexane/2-propanol = 80/20; flow rate 1.0 mL/min; 25°C; $\lambda = 210$ nm)



Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.018	12863863	545348	41.540	63.732
2	26.964	18103563	310347	58.460	36.268
Total		30967426	855696	100.000	100.000

The asymmetric system of **4c** with the chiral **cat.1** (β -ICD) in CH₂Cl₂, enantiomeric excess: 17%, determined by HPLC (Chiralpak IA, hexane/2-propanol = 80/20; flow rate 1.0 mL/min; 25°C; λ = 210 nm) (The impurity substance peak in HPLC chromatogram could be detected in the ¹H NMR, but we could not know the structure of the impurity substance).



Detector A Ch1 210nm								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	13.673	37891202	1475713	61.338	77.393			
2	25.869	23883160	431055	38.662	22.607			
Total		61774361	1906768	100.000	100.000			

The asymmetric system of **4c** with the chiral **cat.1** (β -ICD) in toluene, enantiomeric excess: (-)23%, determined by HPLC (Chiralpak IA, hexane/2-propanol = 80/20; flow rate 1.0 mL/min; 25°C; λ = 210 nm) (The impurity substance peak in HPLC chromatogram could be detected in the ¹H NMR, but we could not know the structure of the impurity substance).

VI. X-Ray crystal structure of 3k and 4k



X-ray structure of **3k** (The H-atoms are omitted for clarity) CCDC NO.1438835



X-ray structure of 4k (The H-atoms are omitted for clarity) CCDC NO. 1438830